|Pediatric Patients age 5 months to less than 12 months||50 mg once daily|
|Pediatric Patients age 1 year to less than 11 years||100 mg once daily|
|Adults and Pediatric Patients age 11 years and older||200 mg once daily|
|Pregnant women, lactating women, patients with glucose-6-phosphate dehydrogenase deficiency||Should not exceed the U.S. Recommended Dietary Allowance (RDA)|
|Patient Population||ASCOR® Once Daily Dose (mg)||Infusion Rate of Diluted ASCOR® Solution (mg/minute)|
|Pediatric Patients age 5 months to less than 12 months||50||1.3|
|Pediatric Patients age 1 year to less than 11 years||100||3.3|
|Adults and Pediatric Patients age 11 years and older||200||33|
The recommended maximum duration of daily treatment with ASCOR® is seven days. If no improvement in scorbutic symptoms is observed after one week of treatment, retreat until resolution of scorbutic symptoms is observed.
Repeat dosing is not recommended in pediatric patients less than 11 years of age.
ASCOR® is vitamin C indicated for the short term (up to 1 week) treatment of
scurvy in adult and pediatric patients age 5 months and older for whom oral
administration is not possible, insufficient or contraindicated.
Limitations of Use:
ASCOR® is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.
Administration site reactions include pain and swelling.
ASCOR® should not be rapidly administered. Rapid intravenous administration (>250 mg/minute) of ASCOR® may cause temporary faintness or nausea, lethargy, flushing, dizziness, and headache.
Acute and chronic oxalate nephropathy have occurred with prolonged administration of high doses of ascorbic acid. ASCOR® is not indicated for prolonged administration. The maximum recommended duration is one week.
In patients with glucose-6-phosphate dehydrogenase deficiency severe hemolysis has occurred.
Ascorbic acid may interfere with laboratory tests based on oxidation-reduction reactions, including blood and urine glucose testing, nitrite and bilirubin levels, and leucocyte count testing. If possible, laboratory tests based on oxidation-reduction reactions should be delayed until 24 hours after infusion of ASCOR®.
Please see accompanying Full Prescribing Information for ASCOR®.
The information contained in this section of the site is intended for U.S. healthcare professionals only.